Finance & Transparency
SPONSOR | EUROS | ACTIVITIES |
---|---|---|
Gilead Sciences Europe Ltd | 428,987.00 | Set-up and 2010 Summit |
Janssen Pharmaceuticals NV | 140,000.00 | Set-up and 2010 Summit |
GlaxoSmithKline Biologicals SA | 30,000.00 | 2010 Summit |
Bristol Myers Squibb EMEA SARL | 50,000.00 | 2010 Summit |
Schering-Plough | 175,000.00 | 2010 Summit |
SPONSOR | EUROS | ACTIVITIES |
---|---|---|
Gilead Sciences Europe Ltd | 250,000.00 | Unrestricted and 2012 Summit |
Janssen Pharmaceuticals NV | 75,000.00 | Educational grant |
Bristol Myers Squibb EMEA SARL | 35,000.00 | 2011/2012activities and 2012 summit |
Gilead Sciences Hellas M.EPE | 15,000.00 | 2011 Call to action |
SPONSOR | EUROS | ACTIVITIES |
---|---|---|
Bristol Myers Squibb EMEA SARL | 45,000.00 | 2013 Activities and Summit 2014 |
Merck Sharp and Dohme | 20,000.00 | 2012 Conference |
Gilead Sciences Europe LTD | 203,000.00 | 2013 Activities and Summit 2014 |
Gilead Sciences Hellas M.EPE | 18,000.00 | Summit 2014 |
Abbvie Pharma S.A. Greece | 70,000.00 | Summit 2014 and 2014 activities |
Bristol Myers Squibb EMEA SARL | 45,000.00 | 2014 Summit and activities |
SPONSOR | EUROS | ACTIVITIES |
---|---|---|
Gilead Sciences Europe Ltd | 180,000.00 | Core funding 2015 and 2016 EU HCV Policy Summit |
Abbvie Pharmaceuticals France | 130,000.00 | 2016 EU HCV Policy Summit |
Bristol Myers Squibb EMEA SARL | 45,000.00 | EU HCV Policy Summit 2016 and the Innovative Finance Initiative to Tackle HCV in Europe |
Bristol Myers Squibb USA | 17,774.00 | EU HCV Policy Summit 2016 and related activities |
Abbvie Pharmaceuticals France | 50, 000.00 | Elimination days in Brussels dedicated to the elimination of HCV in three EU countries |
Abbvie Pharma S.A. Greece | 11,000.00 | National roundtable on the Elimination Manifesto, Athens, September 2016 |
Gilead Sciences Europe Ltd | 348,000.00 | Core funding 2016 and the Innovative Finance Initiative to Tackle HCV in Europe |
Merck Sharp and Dohme | 30, 000.00 | EU HCV Policy Summit 2016 |
SPONSOR | EUROS | ACTIVITIES |
---|---|---|
AbbVie Pharmaceuticals | 45,000 | 2nd EU HCV Policy Summit |
Gilead Sciences Europe Inc | 101,215 | 2nd EU HCV Policy Summit |
MSD | 55,000 | 2nd EU HCV Policy Summit |
Gilead Sciences Europe Inc | 126,000 | Four Mini HCV Policy Summits at the European Parliament |
Gilead Sciences Europe Inc | 103,786 | Newsletter, WEbsite, EU Database, publications |
Gilead Sciences Europe Inc | 18,000 | PROs project |
Call to Action for a Europe free of hepatitis C (24.03.2021)
EU Policymakers Database
HepBCPPA has compiled a database of EU 27 countries and the UK with a list of policymakers and advocates active in the strive for the elimination of hepatitis. e can provide this information on request.
Contact: [email protected]